Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:21 AM
Ignite Modification Date:
2025-12-25 @ 2:21 AM
NCT ID:
NCT05599334
Eligibility Criteria:
Inclusion Criteria:
* Patients will be eligible for inclusion if they fulfill all of the following criteria:
* Age ≥ 18 years at neratinib treatment initiation
* Having received at least one initial dose of neratinib as an extended adjuvant therapy for the treatment of early-stage HER2+ breast cancer, in the context of the EAP in Europe, and between August 01, 2017 and December 31, 2020
* Patients (or next of kin/legal representative, if applicable) who provide written informed consent or non-opposition.
Exclusion Criteria:
* N/A
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05599334
Study Brief:
Protocol Section:
NCT05599334